Laurus Labs invests INR 1.08 billion: Nuvama targets Laurus Labs stock at INR 2,520

Published on 10/20/2026 at 02:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nuvama set a Buy rating and INR 2,520 target on October 16, 2026. Laurus Labs stock reached INR 2,087 on October 19, 2026.

Capital allocation and earnings dates

Laurus Labs invested INR 1.08 billion in KRKA Pharma on October 14, 2026.
Nuvama set an INR 2,520 target for Laurus Labs stock on October 16, 2026.
Laurus Labs reported INR 20.26 billion in first-quarter revenue for fiscal year 2027.

Laurus, INE947Q01028, Illustration mit AI erstellt.

Laurus Labs (INE947Q01028) invested INR 1.08 billion in KRKA Pharma on October 14, 2026, while retaining a 49 percent stake, according to Screener. On October 16, 2026, Nuvama initiated coverage with a Buy rating and an INR 2,520 target, as reported by Business Today.

Three events shape the setup

On July 24, 2026, Laurus Labs reported first-quarter fiscal year 2027 revenue of INR 20.26 billion and net profit of INR 3.62 billion, according to Informist. On October 13, 2026, the company scheduled its September-quarter and first-half results for October 29, 2026, according to Screener.

On October 14, 2026, Laurus Labs disclosed the INR 1.08 billion investment in KRKA Pharma, with its ownership remaining at 49 percent, the same company-announcement record states. The sequence gives investors two measurable reference points before the next report: a larger strategic investment and a scheduled earnings test.

What does the INR 1.08 billion investment change?

The transaction does not change Laurus Labs' reported ownership percentage, but it adds a defined capital-allocation event to the earnings setup. The operating backdrop is also quantified: first-quarter fiscal year 2027 revenue of INR 20.26 billion exceeded the year-earlier quarter's INR 16.53 billion, while net profit reached INR 3.62 billion versus INR 1.94 billion, according to Screener.

Estimates point to a margin test

For the September quarter, the average of five brokerage estimates was INR 21.06 billion in revenue, INR 3.67 billion in net profit and INR 6.39 billion in EBITDA, according to Informist. Kotak Securities projected synthesis revenue at INR 8.80 billion, up 86 percent year over year, while its EBITDA estimate was INR 6.75 billion, up 67 percent year over year. Those figures make the contract development and manufacturing business the clearest operating metric for the upcoming release.

Next reporting date

Laurus Labs is scheduled to publish its September-quarter and first-half fiscal year 2027 results on October 29, 2026, with a conference call scheduled for 5:00 p.m. India Standard Time, according to Screener.

Stock context before results

On October 19, 2026, Laurus Labs reached INR 2,087 on the BSE, a new lifetime high, while the scheduled results kept attention on the September quarter. The combination of the KRKA investment, Nuvama's INR 2,520 target and the upcoming INR 21.06 billion revenue estimate frames the next announcement around capital allocation, growth and margin delivery.

Market context: Market report BSE Sensex.